Video: Prevalence of Long Term HCQ in Retinal Toxicity: Dr. Kathryn Dao (@KDAO2011 ) Dr. Kathryn Dao reviews abstract OP0133, "The Prevalence and Risk Factors of Retinal Toxicity Associated with Long-Term Hydroxychloroquine Use", presented at #EULAR2021. https://t.co/tZyXQhZgLG https://t.co/x6AfItFWEU

• https://bit.ly/2RyGEaa

Tune in to our latest podcast on #EULAR2021 and EULAR IQ. https://t.co/yjId7QNRRR https://t.co/F46FLEilRY

• https://bit.ly/3pqqdsW

#EULAR2021 IL-23 & IL-12/23 coverage in one spot on RheumNow. https://t.co/sut3zubcow https://t.co/f7XDuRyLB9

• https://bit.ly/2TMfPjx

RA after 70: Too Old for bioDMARDs? by Dr. Aurelie Najm #EULAR2021 In RA, the two most common peaks of incidence are 30s and 50s; however a significant % of patients in 70s present with active RA -of early or later onset- and require adapted treatment. https://t.co/w6rxT0FmlP https://t.co/fnvSQcu0Fl

• https://bit.ly/2T0m9n2

Video: Difficult to Treat RA: Look out for Comorbidities: Dr. Aurelie Najm #EULAR2021 https://t.co/71Kx0HmmDm https://t.co/iu2p2EXNof

• https://bit.ly/3pyAB1W

@IainBMcInnes1 @NEJM @JWatch @NEJMres360 #rheumatology #rheumtwitter #MedTwitter #VisualAbstract #WorldASDay #spondyloarthritis #psoriasis #psoriaticarhtritis #MedEd #dermatology #JAKi #EBM https://t.co/dGRi83Wt9x https://t.co/22WacHQZpT

• https://www.nejm.org/doi/full/10.1056/NEJMoa2022516

OP0140 at #EULAR2021: ➡️Obs, prospect Nordic study characterized axSpA pts w/ high BASDAI + ASDAS & multiple bDMARD use (indicating difficult to tx dz) ➡️1 in 10 received at least 3 bDMARDs *⃣Multiple switchers were more often F, had higher b/l dz activity, & psoriasis @Rheumnow https://t.co/syq0szVWKe

⭐️TORTUGA = PII trial that showed filgotinib (Jak1-i) signif improv SPARCC MRI scores (BM edema) in the spine + SIJ vs PBO in pts w/ active AS ⭐️OP0141 = post-hoc analysis that showed stat signif ⬇️ of CANDEN MRI scores (new bone format) w/ filgot at wk12 #EULAR2021 @Rheumnow https://t.co/RIpYIMcx1Q

➡️Netakimab = IL17Ai approved for AS, PsA, & Pso in Russia & Belarus

Clive Kelly presents data from INBUILD on nintedanib in progressive fibrosing RA-ILD over 52 weeks FVC decline -82.6 (41.3) mL in nintedanib vs -199.3 (36.2) mL in placebo (p=0.037) @RheumNow #EULAR2021 Abstr#OP0124 https://t.co/MZwzNoq6LC

⭐️JUNIPERA: RCT of SEC in active ERA & JPsA (2-18yo, most on MTX) -Tx . (TP)1: SEC 75/100 mg till wk 12 -TP2: cont SEC or switch to PBO till wk 104 ⭐️SEC efficacious on JIA ACR30/70 ⭐️74% w/ resolution of enthes ⭐️Median T2flare in PBO in TP2 = 453d LB0004 #EULAR2021 @Rheumnow https://t.co/JsG2pXz9r6

What to tell pts about diet? *⃣Nutrition plays a role in inflammation in RMD & co-morbidities. What you eat matters! *⃣ LImit salt, replace w/ herbs *⃣ Consume low glycemic index foods. Soda ⬆️risk of RA in women *⃣⬆️omega-3 ⬇️omega-6 (dairy, eggs) #EULAR2021 @Rheumnow

#EULAR2021 POS0236 Comparison of work productivity b/w CBP w & w/o AxSpA - 2 years from SPACE cohort ⭐️AxSpA showed significant ⬇️ in work productivity loss (WPL) compared to CBP wo AxSpA Can use to counsel AxSpA patients that we have effective Rx for return to work @RheumNow

#EULAR2021 POS0237: Gut dysbiosis linked to worse disease status in axSpA. ⭐️Dysbiosis in 33% of AxSpA vs 17% of controls wo rheumatic disease ⭐️Gut dysbiosis associated with worsening disease activity @RheumNow https://t.co/rRl4Zbs7xc